カテゴリー： 世界, 医療/バイオ, MarketsandMarkets

世界の血液型タイピング市場（～2028年）：製品別（消耗品、機器、サービス）、検査種類別（ABO、抗原、抗体、HLA）、手法別（アッセイベース、PCR、マイクロアレイ、大規模並列シーケンス）、エンドユーザー別（病院、血液バンク）、地域別

【英語タイトル】Blood Group Typing Market by Product (Consumables, Instruments, Services), Test Type (ABO, Antigen, Antibody, HLA), Technique (Assay-based, PCR, Microarray, Massively Parallel Sequencing), End User (Hospital, Blood Banks), Region - Global Forecast to 2028

MarketsandMarketsが出版した調査資料（MD5210-23）・商品コード：MD5210-23
・発行会社（調査会社）：MarketsandMarkets
・発行日：2023年9月20日
・ページ数：214
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥742,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥997,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,222,500見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

"血液型タイピング市場は2023年に推定20億米ドルと評価され、予測期間中のCAGRは8.7％で、2028年には30億米ドルに達すると予測"
重度の分娩後出血（分娩時または分娩後の出血）は、世界的に妊産婦死亡の主な原因となっています。さらに、小児貧血、外傷、先天性血液疾患も輸血を必要とするその他の緊急疾患です。これらの患者を管理するには、血液や血液製剤の輸血を含め、緊急かつタイムリーな治療が必要です。輸血件数の全体的な増加により、輸血された血液の安全性と適合性を確保するために血液型検査法の採用が増加しています。これが市場全体の成長を促進しています。

"予測期間中、血液型タイピング市場において、検査タイプ別では抗体スクリーニング分野が最も高い成長率を占める"
血液型タイピング市場は、検査タイプ別にABO血液検査＆Rhタイピング、抗体スクリーニング、HLAタイピング、クロスマッチング検査、抗原タイピングに二分されます。血液型タイピング市場における抗体スクリーニング分野は、自己免疫疾患やがんなどの疾患の発生率の増加により、大幅な成長を遂げています。また、慢性疾患の増加を受けて、抗原特異的治療法の研究開発への注目が高まっていることも、抗体スクリーニング法の使用を増加させています。

"予測期間中の血液型タイピング市場において、技術別ではPCRベースおよびマイクロアレイ技術分野が最も高い成長率を占める"
世界の血液型タイピング市場は、アッセイベース技術、PCRベースおよびマイクロアレイ技術、超並列シーケンス技術、その他の技術に二分されます。現在、血液型タイピング市場で最も高い成長率を示しているのは、PCRベースおよびマイクロアレイ技術分野です。PCRベースの技術は、遺伝子レベルで希少な血液型抗原を正確に同定し特徴付ける強力なツールとして登場しました。しかし、PCR法ではスループットとマルチプレックス能力に限界があります。これらの限界を克服するために、マイクロアレイプラットフォームが開発されました。マイクロアレイプラットフォームは、基本的なPCR法よりも血液型抗原に関する詳細な情報を提供します。従来の方法よりも精度が高いなどの利点があるため、エンドユーザーの間で採用が増加しています。

"アジア太平洋：最も急成長している地域の血液型タイピング市場"
世界の血液型タイピング市場は、北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカに区分されます。献血や定期的な健康診断の重要性に関する認識を高めるための政府の取り組み、継続的な医療費の増加、インドと中国における病院数の増加、インド、中国、日本全体における診断手順の研究基盤の強化などの要因により、アジア太平洋市場は予測期間中に最も高い成長が見込まれています。さらに、政府の支援的な規制は、予測期間中のこの市場の成長をさらに後押しするでしょう。

血液型タイピング市場の主要参入企業のプロファイルの内訳です：
- 企業タイプ別 ティア1-40％、ティア2-30％、ティア3-30％
- 役職別 Cレベル-27％、Dレベル-18％、その他-55％
- 地域別 北米-51％、ヨーロッパ-21％、アジア太平洋-18％、中南米-6％、中東・アフリカ-4％

この市場の主要企業は、Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), Thermo Fisher Scientific Inc. (US), Immucor, Inc. (US), Danaher (US), Merck KGaA (Germany), Quotient Limited (Switzerland), Novacyt (France), BAG Health Care GmbH (Germany), Rapid Labs Ltd (UK), Agena Bioscience, Inc. (US), Biorex Diagnostics (UK), HUMAN Gesellschaft für Biochemica und Diagnostica mbH (Germany), Prestige Diagnostics (UK), Span Diagnostics SARL (France), DIALAB GmbH (Austria), Lorne Laboratories Limited (UK), Atlas Medical GmbH (Germany), Torax Biosciences Limited (Northern Ireland), Fortress Diagnostics (UK), AXO Science (France), Maxwin Health Care Pvt. Ltd. (India), Anamol Laboratories Pvt. Ltd. (India), J. Mitra & Co. Pvt. Ltd. (India), and MedSource Ozone Biomedicals Pvt. Ltd. (India)などが含まれます。

調査範囲：
この調査レポートは、血液型タイピング市場を製品＆サービス（消耗品、機器、サービス＆ソフトウェア）、検査タイプ（ABO血液検査＆Rhタイピング、抗体スクリーニング、HLAタイピング、クロスマッチング検査、抗原タイピング）、技術（アッセイベース技術、PCRベース技術、マイクロアレイ技術、大規模並列シーケンス技術、その他の技術）、エンドユーザー（病院、血液銀行、臨床検査室、その他のエンドユーザー）、地域（北米、ヨーロッパ、アジア太平洋、中南米、中東＆アフリカ）で分類しています。本レポートでは、血液型タイピング市場の成長に影響を与える促進要因、阻害要因、機会などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、ソリューションとサービス、主要戦略、買収、契約に関する洞察を提供します。血液型分類市場に関連する新製品およびサービスの発表と最近の動向、血液型タイピング市場のエコシステムにおける今後の新興企業の競合分析もカバーしています。

このレポートを購入する理由：
本レポートは、血液型タイピング市場全体およびサブセグメントの収益数の最も近い近似値に関する情報を提供し、この市場の市場リーダー／新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、利害関係者が市場の脈動を理解するのに役立ち、主要な市場促進要因、阻害要因、機会に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します：
- 血液型検査市場の成長に影響を与える主な促進要因（慢性疾患の有病率の増加、献血を必要とする外科手術の増加、輸血を必要とする交通事故、緊急事態、外傷事例の増加、出生前検査における血液型検査の需要の増加、法医学における血液型検査の高い利用率、血液型検査の広範な研究開発、輸血に関する厳しい規制基準）、抑制要因（代替血液の出現）、機会（新興国における成長機会）の分析を行っています。
- 製品開発/イノベーション：血液型タイピング市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察を掲載しています。
- 市場開発：有利な市場に関する包括的情報-当レポートでは、さまざまな地域の血液型タイピング市場を分析しています。
- 市場の多様化：血液型分類市場における新製品＆サービス、未開拓の地域、最近の開発、投資に関する詳細な情報を記載しています。
- 競合評価：Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), Thermo Fisher Scientific Inc. (US), and Immucor, Inc. (US)など、血液型タイピング市場戦略における主要企業の市場シェア、成長戦略、サービス内容を詳細に評価します。

1.イントロダクション
2.調査方法
3.エグゼクティブサマリー
4.プレミアムインサイト
5.市場概要
6.血液型タイピングの市場分析：製品・サービス別
7.血液型タイピングの市場分析：検査種類別
8.血液型タイピングの市場分析：手法別
9.血液型タイピングの市場分析：エンドユーザー別
10.血液型タイピングの市場分析：地域別
11.競争状況
12.企業情報
13.付録

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS & EXCLUSIONS 29
1.3 STUDY SCOPE 29
1.3.1 BLOOD GROUP TYPING MARKET 29
1.3.2 GEOGRAPHIC SCOPE 30
1.3.3 YEARS CONSIDERED 30
1.4 CURRENCY 31
1.5 LIMITATIONS 31
1.6 STAKEHOLDERS 31
1.7 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.2 RESEARCH APPROACH 33
FIGURE 1 BLOOD GROUP TYPING MARKET: RESEARCH DESIGN METHODOLOGY 33
2.2.1 SECONDARY DATA 33
2.2.1.1 Key data from secondary sources 34
2.2.2 PRIMARY DATA 35
2.2.2.1 Primary sources 36
2.2.2.2 Key data from primary sources 37
2.2.2.3 Key industry insights 38
2.2.2.4 Breakdown of primary interviews 38
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 38
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39
2.3 MARKET SIZE ESTIMATION 39
2.3.1 BOTTOM-UP APPROACH 40
2.3.1.1 Approach 1: Company revenue estimation approach 40
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 40
2.3.1.2 Approach 2: Presentations of companies and primary interviews 40
2.3.1.3 Growth forecast 41
2.3.1.4 CAGR projections 41
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
2.3.2 TOP-DOWN APPROACH 41
FIGURE 6 BLOOD GROUP TYPING MARKET: TOP-DOWN APPROACH 42
 
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 43
FIGURE 7 DATA TRIANGULATION METHODOLOGY 43
2.5 MARKET SHARE ANALYSIS 44
2.6 STUDY ASSUMPTIONS 44
2.7 GROWTH RATE ASSUMPTIONS 44
2.8 RISK ASSESSMENT 45
2.8.1 RISK ASSESSMENT: BLOOD GROUP TYPING MARKET 45
2.9 RECESSION IMPACT 45
3 EXECUTIVE SUMMARY 47
FIGURE 8 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE,
2023 VS. 2028 (USD MILLION) 47
FIGURE 9 BLOOD GROUP TYPING MARKET, BY TEST TYPE,
2023 VS. 2028 (USD MILLION) 48
FIGURE 10 BLOOD GROUP TYPING MARKET, BY TECHNIQUE,
2023 VS. 2028 (USD MILLION) 48
FIGURE 11 BLOOD GROUP TYPING MARKET, BY END USER,
2023 VS. 2028 (USD MILLION) 49
FIGURE 12 BLOOD GROUP TYPING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 49
4 PREMIUM INSIGHTS 51
4.1 BLOOD GROUP TYPING MARKET OVERVIEW 51
FIGURE 13 INCREASING PREVALENCE OF CHRONIC CONDITIONS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD 51
4.2 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 51
FIGURE 14 CONSUMABLES SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028 51
4.3 BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2023 VS. 2028 52
FIGURE 15 ABO BLOOD TESTS & RH TYPING SEGMENT TO DOMINATE MARKET IN 2028 52
4.4 BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2023 VS. 2028 52
FIGURE 16 ASSAY-BASED TECHNIQUES SEGMENT TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING FORECAST PERIOD 52
4.5 BLOOD GROUP TYPING MARKET, BY END USER, 2023 VS. 2028 53
FIGURE 17 HOSPITALS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028 53
4.6 BLOOD GROUP TYPING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN BLOOD GROUP TYPING MARKET DURING FORECAST PERIOD 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 19 BLOOD GROUP TYPING MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 54
5.2.1 DRIVERS 54
5.2.1.1 Increasing prevalence of chronic diseases and rising number of surgical procedures necessitating need for blood donations 54
FIGURE 20 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 2015–2030 (MILLION INDIVIDUALS) 55
5.2.1.2 Growing number of road accidents, emergencies, and trauma cases necessitating blood transfusions 56
5.2.1.3 Increasing demand for blood group typing in prenatal testing 56
5.2.1.4 High usage of blood group typing in forensic sciences 57
5.2.1.5 Extensive R&D in blood typing 57
5.2.1.6 Stringent regulatory standards for blood transfusion 57
TABLE 1 LIST OF PRODUCTS CBER REGULATES 58
5.2.2 RESTRAINTS 59
5.2.2.1 Emergence of blood alternatives 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Growth opportunities in emerging economies 59
5.3 PRICING ANALYSIS 60
5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS 60
TABLE 2 INDICATIVE PRICING FOR BLOOD GROUP TYPING PRODUCTS 60
5.3.2 AVERAGE SELLING PRICE OF BLOOD GROUP TYPING PRODUCTS, BY KEY PLAYER 60
TABLE 3 AVERAGE SELLING PRICE OF BLOOD GROUP TYPING PRODUCTS 60
5.4 PATENT ANALYSIS 61
FIGURE 21 PATENT ANALYSIS FOR BLOOD GROUP TYPING REAGENTS (JANUARY 2013–DECEMBER 2022) 61
5.4.1 LIST OF MAJOR PATENTS 62
5.5 VALUE CHAIN ANALYSIS 62
FIGURE 22 VALUE CHAIN ANALYSIS OF BLOOD GROUP TYPING MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 63
5.6 SUPPLY CHAIN ANALYSIS 63
FIGURE 23 BLOOD GROUP TYPING MARKET: SUPPLY CHAIN ANALYSIS 64
5.7 ECOSYSTEM ANALYSIS 64
FIGURE 24 BLOOD GROUP TYPING MARKET: ECOSYSTEM ANALYSIS 65
5.7.1 BLOOD GROUP TYPING MARKET: ROLE IN ECOSYSTEM 65
5.8 PORTER’S FIVE FORCES ANALYSIS 65
TABLE 4 BLOOD GROUP TYPING MARKET: PORTER’S FIVE FORCES ANALYSIS 66
5.8.1 THREAT OF NEW ENTRANTS 66
5.8.2 THREAT OF SUBSTITUTES 66
5.8.3 BARGAINING POWER OF BUYERS 66
5.8.4 BARGAINING POWER OF SUPPLIERS 66
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.9 REGULATORY LANDSCAPE 67
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
TABLE 7 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
5.9.1 NORTH AMERICA 68
5.9.1.1 US 68
5.9.1.2 Canada 68
5.9.2 EUROPE 68
TABLE 9 EUROPE: CLASSIFICATION OF DEVICES 69
5.9.3 ASIA PACIFIC 69
5.9.3.1 China 69
5.9.3.2 Japan 69
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 70
5.9.3.3 India 70
5.9.4 LATIN AMERICA 70
5.9.4.1 Brazil 70
5.9.5 MIDDLE EAST 71
5.10 TRADE ANALYSIS 71
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 71
TABLE 11 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 71
TABLE 12 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 71
5.11 TECHNOLOGY ANALYSIS 72
5.12 KEY CONFERENCES & EVENTS IN 2023–2024 73
TABLE 13 BLOOD GROUP TYPING MARKET: DETAILED LIST OF CONFERENCES & EVENTS 73
5.13 PESTLE ANALYSIS 74
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
FIGURE 25 REVENUE SHIFT IN BLOOD GROUP TYPING MARKET 75
5.15 KEY STAKEHOLDERS & BUYING CRITERIA 76
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 76
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BLOOD GROUP TYPING PRODUCTS 76
TABLE 14 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF BLOOD GROUP TYPING PRODUCTS (%) 76
5.15.2 BUYING CRITERIA 77
FIGURE 27 KEY BUYING CRITERIA FOR BLOOD GROUP TYPING PRODUCTS 77
TABLE 15 KEY BUYING CRITERIA FOR BLOOD GROUP TYPING PRODUCTS 77
5.15.3 CASE STUDY ANALYSIS 77
 
6 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE 79
6.1 INTRODUCTION 80
TABLE 16 BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 80
6.2 CONSUMABLES 80
TABLE 17 KEY CONSUMABLES AVAILABLE IN MARKET 81
TABLE 18 BLOOD GROUP TYPING CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 81
TABLE 19 BLOOD GROUP TYPING CONSUMABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 82
6.2.1 ANTISERA REAGENTS 82
6.2.1.1 Increasing demand for cost-effective blood typing solutions to support uptake of antisera reagents 82
TABLE 20 ANTISERA REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 82
6.2.2 ANTI-HUMAN GLOBULIN REAGENTS 83
6.2.2.1 Increasing number of organ transplantations to drive uptake of AHG reagents 83
TABLE 21 ANTI-HUMAN GLOBULIN REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 83
6.2.3 RED BLOOD CELL REAGENTS 83
6.2.3.1 Higher compatibility of red blood cell reagents with variety of blood group typing techniques to support uptake 83
TABLE 22 RED BLOOD CELL REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 84
6.2.4 BLOOD BANK SALINE 84
6.2.4.1 Ability of blood bank saline to preserve integrity of RBCs to support market growth 84
TABLE 23 BLOOD BANK SALINE MARKET, BY REGION, 2021–2028 (USD MILLION) 85
6.3 INSTRUMENTS 85
6.3.1 GROWING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO BOOST DEMAND FOR BLOOD GROUP TYPING INSTRUMENTS 85
TABLE 24 KEY INSTRUMENTS AVAILABLE IN MARKET 86
TABLE 25 BLOOD GROUP TYPING INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 86
6.4 SERVICES & SOFTWARE 87
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH IN MARKET SEGMENT 87
TABLE 26 BLOOD GROUP TYPING SERVICES & SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION) 87
7 BLOOD GROUP TYPING MARKET, BY TEST TYPE 88
7.1 INTRODUCTION 89
TABLE 27 BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 89
7.2 ABO BLOOD TESTS & RH TYPING 89
7.2.1 GROWING AWARENESS OF IMPORTANCE OF BLOOD DONATION TO DRIVE GROWTH 89
TABLE 28 BLOOD GROUP TYPING MARKET FOR ABO BLOOD TESTS & RH TYPING, BY REGION, 2021–2028 (USD MILLION) 90
7.3 ANTIBODY SCREENING 90
7.3.1 INCREASING INCIDENCE OF CANCER AND AUTOIMMUNE DISORDERS TO SUPPORT GROWTH 90
TABLE 29 BLOOD GROUP TYPING MARKET FOR ANTIBODY SCREENING, BY REGION, 2021–2028 (USD MILLION) 91
7.4 HLA TYPING 91
7.4.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO STIMULATE DEMAND FOR HLA TYPING 91
TABLE 30 BLOOD GROUP TYPING MARKET FOR HLA TYPING, BY REGION, 2021–2028 (USD MILLION) 92
7.5 CROSS-MATCHING TESTS 92
7.5.1 GROWING NEED FOR BLOOD TRANSFUSION TO PROPEL MARKET GROWTH 92
TABLE 31 BLOOD GROUP TYPING MARKET FOR CROSS-MATCHING TESTS, BY REGION, 2021–2028 (USD MILLION) 93
7.6 ANTIGEN TYPING 93
7.6.1 INCREASING CASES OF INCORRECT BLOOD TRANSFUSION TO FUEL GROWTH 93
TABLE 32 BLOOD GROUP TYPING MARKET FOR ANTIGEN TYPING, BY REGION, 2021–2028 (USD MILLION) 94
8 BLOOD GROUP TYPING MARKET, BY TECHNIQUE 95
8.1 INTRODUCTION 96
TABLE 33 BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 96
8.2 ASSAY-BASED TECHNIQUES 96
8.2.1 AUTOMATION, SENSITIVITY, OBJECTIVITY, AND ADAPTABILITY OF ASSAY-BASED TECHNIQUES TO BOOST ADOPTION 96
TABLE 34 BLOOD GROUP TYPING MARKET FOR ASSAY-BASED TECHNIQUES, BY REGION, 2021–2028 (USD MILLION) 97
8.3 PCR-BASED AND MICROARRAY TECHNIQUES 97
8.3.1 HIGH ACCURACY OF PCR-BASED AND MICROARRAY TECHNIQUES TO SUPPORT GROWTH 97
TABLE 35 BLOOD GROUP TYPING MARKET FOR PCR-BASED AND MICROARRAY TECHNIQUES, BY REGION, 2021–2028 (USD MILLION) 98
8.4 MASSIVELY PARALLEL SEQUENCING 98
8.4.1 ABILITY TO DETECT LOW-FREQUENCY ALLELES TO DRIVE DEMAND FOR MPS TECHNIQUES 98
TABLE 36 BLOOD GROUP TYPING MARKET FOR MASSIVELY PARALLEL SEQUENCING, BY REGION, 2021–2028 (USD MILLION) 98
8.5 OTHER TECHNIQUES 99
TABLE 37 BLOOD GROUP TYPING MARKET FOR OTHER TECHNIQUES, BY REGION, 2021–2028 (USD MILLION) 99
 
9 BLOOD GROUP TYPING MARKET, BY END USER 100
9.1 INTRODUCTION 101
TABLE 38 BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 101
9.2 PRIMARY NOTES 101
9.2.1 KEY PRIMARY INSIGHTS 101
9.3 HOSPITALS 102
9.3.1 INCREASING NUMBER OF HOSPITALS TO BOOST GROWTH 102
TABLE 39 BLOOD GROUP TYPING MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 102
9.4 BLOOD BANKS 103
9.4.1 GROWING NUMBER OF BLOOD DONATIONS TO PROPEL MARKET GROWTH 103
TABLE 40 BLOOD GROUP TYPING MARKET FOR BLOOD BANKS, BY REGION, 2021–2028 (USD MILLION) 103
9.5 CLINICAL LABORATORIES 104
9.5.1 GROWING PREVALENCE OF BLOOD DISORDERS TO BOLSTER GROWTH 104
TABLE 41 BLOOD GROUP TYPING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 104
9.6 OTHER END USERS 104
TABLE 42 BLOOD GROUP TYPING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 105
10 BLOOD GROUP TYPING MARKET, BY REGION 106
10.1 INTRODUCTION 107
TABLE 43 BLOOD GROUP TYPING MARKET, BY REGION, 2021–2028 (USD MILLION) 107
10.2 NORTH AMERICA 107
FIGURE 28 NORTH AMERICA: BLOOD GROUP TYPING MARKET SNAPSHOT 109
TABLE 44 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 45 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 110
TABLE 46 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 110
TABLE 47 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 111
TABLE 48 NORTH AMERICA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 111
10.2.1 NORTH AMERICA: RECESSION IMPACT 111
10.2.2 US 112
10.2.2.1 Increasing prevalence of chronic conditions to drive market growth 112
TABLE 49 ESTIMATED NUMBER OF SINGLE ORGAN TRANSPLANTS PERFORMED IN US 112
TABLE 50 US: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 113
TABLE 51 US: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 113
TABLE 52 US: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 114
TABLE 53 US: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 114
10.2.3 CANADA 114
10.2.3.1 Increasing incidence of blood cancer to boost market 114
TABLE 54 CANADA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 115
TABLE 55 CANADA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 115
TABLE 56 CANADA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 116
TABLE 57 CANADA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 116
10.3 EUROPE 116
TABLE 58 EUROPE: BLOOD GROUP TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 59 EUROPE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 117
TABLE 60 EUROPE: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 118
TABLE 61 EUROPE: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 118
TABLE 62 EUROPE: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 118
10.3.1 EUROPE: RECESSION IMPACT 119
10.3.2 GERMANY 119
10.3.2.1 Increasing healthcare expenditure to drive market growth 119
TABLE 63 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 120
TABLE 64 GERMANY: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 120
TABLE 65 GERMANY: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 120
TABLE 66 GERMANY: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 121
TABLE 67 GERMANY: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 121
10.3.3 UK 121
10.3.3.1 Growing number of road accidents to propel market growth 121
TABLE 68 UK: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 122
TABLE 69 UK: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 122
TABLE 70 UK: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 123
TABLE 71 UK: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 123
 
10.3.4 FRANCE 123
10.3.4.1 Rising R&D expenditure in France to drive market growth 123
TABLE 72 FRANCE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 124
TABLE 73 FRANCE: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 124
TABLE 74 FRANCE: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 125
TABLE 75 FRANCE: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 125
10.3.5 ITALY 125
10.3.5.1 Increasing number of blood donors to favor market growth 125
TABLE 76 ITALY: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 126
TABLE 77 ITALY: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 126
TABLE 78 ITALY: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 127
TABLE 79 ITALY: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 127
10.3.6 SPAIN 127
10.3.6.1 Consolidation of laboratories in Spain to support market growth 127
TABLE 80 SPAIN: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 128
TABLE 81 SPAIN: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 128
TABLE 82 SPAIN: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 128
TABLE 83 SPAIN: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 129
10.3.7 REST OF EUROPE 129
TABLE 84 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY 130
TABLE 85 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 130
TABLE 86 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 130
TABLE 87 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 131
TABLE 88 REST OF EUROPE: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 131
10.4 ASIA PACIFIC 132
FIGURE 29 ASIA PACIFIC: BLOOD GROUP TYPING MARKET SNAPSHOT 133
TABLE 89 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 90 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 134
TABLE 91 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 134
TABLE 92 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 135
TABLE 93 ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 135
10.4.1 ASIA PACIFIC: RECESSION IMPACT 135
10.4.2 CHINA 136
10.4.2.1 Growing public access to modern healthcare to drive market growth 136
TABLE 94 CHINA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020 136
TABLE 95 CHINA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 137
TABLE 96 CHINA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 137
TABLE 97 CHINA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 138
TABLE 98 CHINA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 138
10.4.3 JAPAN 138
10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan 138
TABLE 99 JAPAN: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 139
TABLE 100 JAPAN: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 139
TABLE 101 JAPAN: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 140
TABLE 102 JAPAN: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 140
10.4.4 INDIA 140
10.4.4.1 Increasing private & public investments in healthcare system to drive market growth 140
TABLE 103 INDIA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 141
TABLE 104 INDIA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 142
TABLE 105 INDIA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 142
TABLE 106 INDIA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 142
10.4.5 REST OF ASIA PACIFIC 143
TABLE 107 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 144
TABLE 108 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 144
TABLE 109 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 145
TABLE 110 REST OF ASIA PACIFIC: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 145
10.5 LATIN AMERICA 145
10.5.1 IMPLEMENTATION OF UNIVERSAL HEALTH COVERAGE TO SUPPORT MARKET GROWTH 145
TABLE 111 BRAZIL: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2020 146
TABLE 112 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 146
TABLE 113 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 147
TABLE 114 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 147
TABLE 115 LATIN AMERICA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 148
10.5.2 LATIN AMERICA: RECESSION IMPACT 148
10.6 MIDDLE EAST & AFRICA 148
10.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 148
TABLE 116 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 149
TABLE 117 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY TEST TYPE, 2021–2028 (USD MILLION) 150
TABLE 118 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 150
TABLE 119 MIDDLE EAST & AFRICA: BLOOD GROUP TYPING MARKET, BY END USER, 2021–2028 (USD MILLION) 151
11 COMPETITIVE LANDSCAPE 152
11.1 OVERVIEW 152
11.2 STRATEGIES OF KEY PLAYERS 152
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BLOOD GROUP TYPING MARKET 153
TABLE 120 OVERVIEW OF STRATEGIES DEPLOYED BY KEY BLOOD GROUP TYPING MANUFACTURING COMPANIES 153
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 154
FIGURE 30 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN BLOOD GROUP TYPING MARKET 154
11.4 MARKET SHARE ANALYSIS 155
FIGURE 31 BLOOD GROUP TYPING MARKET SHARE, BY KEY PLAYER (2022) 155
TABLE 121 BLOOD GROUP TYPING MARKET: DEGREE OF COMPETITION 155
11.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS (2022) 157
11.5.1 LIST OF EVALUATED VENDORS 157
11.5.2 STARS 157
11.5.3 EMERGING LEADERS 157
11.5.4 PERVASIVE PLAYERS 157
11.5.5 PARTICIPANTS 157
FIGURE 32 BLOOD GROUP TYPING MARKET: COMPANY EVALUATION QUADRANT, 2022 158
11.6 COMPETITIVE EVALUATION QUADRANT FOR START-UPS/SMES (2022) 159
11.6.1 PROGRESSIVE COMPANIES 159
11.6.2 STARTING BLOCKS 159
11.6.3 RESPONSIVE COMPANIES 159
11.6.4 DYNAMIC COMPANIES 159
FIGURE 33 BLOOD GROUP TYPING MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022 160
11.6.5 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 161
FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN BLOOD GROUP TYPING MARKET 161
TABLE 122 BLOOD GROUP TYPING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 161
TABLE 123 COMPANY PRODUCT & SERVICE FOOTPRINT 162
TABLE 124 COMPANY REGIONAL FOOTPRINT 162
TABLE 125 BLOOD GROUP TYPING MARKET: DETAILED LIST OF KEY START-UPS/SMES 162
11.7 COMPETITIVE SCENARIO 163
11.7.1 PRODUCT LAUNCHES 163
TABLE 126 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–AUGUST 2023) 163
11.7.2 DEALS 164
TABLE 127 KEY DEALS (JANUARY 2020–AUGUST 2023) 164
12 COMPANY PROFILES 165
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1 KEY PLAYERS 165
12.1.1 BIO-RAD LABORATORIES, INC. 165
TABLE 128 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 165
FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 166
12.1.2 QUIDELORTHO CORPORATION 170
TABLE 129 QUIDELORTHO CORPORATION: BUSINESS OVERVIEW 170
FIGURE 36 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022) 171
12.1.3 GRIFOLS, S.A. 174
TABLE 130 GRIFOLS, S.A.: BUSINESS OVERVIEW 174
FIGURE 37 GRIFOLS, S.A.: COMPANY SNAPSHOT (2022) 175
12.1.4 THERMO FISHER SCIENTIFIC INC. 179
TABLE 131 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 179
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 180
12.1.5 IMMUCOR, INC. 182
TABLE 132 IMMUCOR, INC.: BUSINESS OVERVIEW 182
12.1.6 QUOTIENT LIMITED 185
TABLE 133 QUOTIENT LIMITED: BUSINESS OVERVIEW 185
FIGURE 39 QUOTIENT LIMITED: COMPANY SNAPSHOT (2021) 186
12.1.7 DANAHER 189
TABLE 134 DANAHER: BUSINESS OVERVIEW 189
FIGURE 40 DANAHER: COMPANY SNAPSHOT (2022) 190
12.1.8 MERCK KGAA 192
TABLE 135 MERCK KGAA: BUSINESS OVERVIEW 192
FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT (2022) 193
12.1.9 NOVACYT 194
TABLE 136 NOVACYT: BUSINESS OVERVIEW 194
FIGURE 42 NOVACYT: COMPANY SNAPSHOT (2022) 194
12.1.10 BAG HEALTH CARE GMBH 196
TABLE 137 BAG HEALTH CARE GMBH: BUSINESS OVERVIEW 196
12.1.11 RAPID LABS LTD. 198
TABLE 138 RAPID LABS LTD.: BUSINESS OVERVIEW 198
12.2 OTHER PLAYERS 200
12.2.1 AGENA BIOSCIENCE, INC. 200
TABLE 139 AGENA BIOSCIENCE, INC.: COMPANY OVERVIEW 200
12.2.2 BIOREX DIAGNOSTICS 201
TABLE 140 BIOREX DIAGNOSTICS: COMPANY OVERVIEW 201
12.2.3 HUMAN GESELLSCHAFT FÜR BIOCHEMICA UND DIAGNOSTICA MBH 202
TABLE 141 HUMAN GESELLSCHAFT FÜR BIOCHEMICA UND DIAGNOSTICA MBH: COMPANY OVERVIEW 202
12.2.4 PRESTIGE DIAGNOSTICS 203
TABLE 142 PRESTIGE DIAGNOSTICS: COMPANY OVERVIEW 203
12.2.5 DIALAB GMBH 204
TABLE 143 DIALAB GMBH: COMPANY OVERVIEW 204
12.2.6 LORNE LABORATORIES LIMITED 205
TABLE 144 LORNE LABORATORIES LIMITED: COMPANY OVERVIEW 205
12.2.7 ATLAS MEDICAL GMBH 206
TABLE 145 ATLAS MEDICAL GMBH: COMPANY OVERVIEW 206
12.2.8 TORAX BIOSCIENCES LIMITED 207
TABLE 146 TORAX BIOSCIENCES LIMITED: COMPANY OVERVIEW 207
12.2.9 FORTRESS DIAGNOSTICS 208
TABLE 147 FORTRESS DIAGNOSTICS: COMPANY OVERVIEW 208
12.2.10 AXO SCIENCE 209
TABLE 148 AXO SCIENCE: COMPANY OVERVIEW 209
12.2.11 MAXWIN HEALTH CARE PVT. LTD. 209
TABLE 149 MAXWIN HEALTH CARE PVT. LTD.: COMPANY OVERVIEW 209
12.2.12 ANAMOL LABORATORIES PVT. LTD. 210
TABLE 150 ANAMOL LABORATORIES PVT. LTD.: COMPANY OVERVIEW 210
12.2.13 J. MITRA & CO. PVT. LTD. 211
TABLE 151 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW 211
12.2.14 MEDSOURCE OZONE BIOMEDICALS PVT. LTD. 212
TABLE 152 MEDSOURCE OZONE BIOMEDICALS PVT. LTD.: COMPANY OVERVIEW 212
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 213
13.1 DISCUSSION GUIDE 213
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 217
13.3 CUSTOMIZATION OPTIONS 219
13.4 RELATED REPORTS 219
13.5 AUTHOR DETAILS 220



★調査レポート[世界の血液型タイピング市場（～2028年）：製品別（消耗品、機器、サービス）、検査種類別（ABO、抗原、抗体、HLA）、手法別（アッセイベース、PCR、マイクロアレイ、大規模並列シーケンス）、エンドユーザー別（病院、血液バンク）、地域別] (コード：MD5210-23)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の血液型タイピング市場（～2028年）：製品別（消耗品、機器、サービス）、検査種類別（ABO、抗原、抗体、HLA）、手法別（アッセイベース、PCR、マイクロアレイ、大規模並列シーケンス）、エンドユーザー別（病院、血液バンク）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の血液分析装置＆試薬市場（～2029年）：製品別（機器（PoC、半自動）、試薬、消耗品、サービス）、価格別（高、中、低）、用途別（貧血、血液がん）、エンドユーザー別（病院、CTL、政府研究所、血液バンク）
  • 世界のゲノム個別化医療市場（2022-2032）：技術別（NGSプラットフォーム、RT-PCR、マイクロアレイ、遺伝子解析装置、その他）、検査種類別（がん検査、感染症検査、希少疾患検査、自己免疫疾患検査、産科検査、その他）、エンドユーザー別（学術＆研究機関、診断センター、その他）、地域別
  • 世界のHIV診断市場（～2030年）：製品別（ソフトウェア＆サービス、機器、消耗品）、検査種類別（抗体検査、ウイルス負荷検査、乳児早期診断用検査、CD4検査、ウイルス同定用検査）、エンドユーザー別、地域別
  • 世界の呼吸器診断市場予測（2024年-2032年）：製品・サービス種類別（機器＆サービス、アッセイ＆試薬、サービス＆ソフトウェア）、検査種類別（機械的検査、閉塞性睡眠時無呼吸（OSA）診断検査、画像検査、従来の診断検査、 分子診断検査、その他）、疾患別（結核、喘息、慢性閉塞性肺疾患（COPD）、肺癌、その他）、エンドユーザー別（病院、診療所、レファレンス＆臨床検査室、その他）、地域別
  • 世界の医薬品無菌性試験市場（2023-2030）：製品種類別（装置、サービス）、種類別（アウトソーシング、インハウス）、検査種類別、サンプル別、エンドユーザー別、地域別
  • 世界の遺伝子発現解析市場（2022-2032）：技術別（ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）、マイクロアレイ、その他）、製品種類別（装置、試薬・消耗品、サービス）、エンドユーザー別（創薬・開発、診断研究所、学術研究センター）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆